(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...

First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumerationExpands CNSide contracted payer ...

Cerenome's CNSide Diagnostics launched two CSF-based molecular profiling tests for CNS cancers, analyzing DNA and RNA.

Roche supplied two molecular testing systems and in the DRC to support PCR test validation for Bundibugyo virus amid Ebola outbreak.

This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites.

Some infections no longer respond to common antibiotics because of antimicrobial resistance. Learn how resistance genes work, ...

The FDA approved a new targeted therapy called Lyrfigtu (lirafugratinib) on September 23, 2026, for a specific type of bile ...

A Colombian study of 478 patients found that routine cerebrospinal fluid white cell counts and protein levels could predict ...

Leishmaniasis, a parasitic disease transmitted by sandflies, remains one of the most under-recognized threats to global ...

Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique (INSP), which is supporting the DRC's Ministry of Health-led Ebola response. Roche will ...

Researchers from the University Hospital of Bonn and the University of Bonn have succeeded in dramatically rejuvenating human ...

Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still ...